Overcoming Resistance to Targeted Therapies in Cancer

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

The recent discovery of oncogenic drivers and subsequent development of novel targeted strategies has significantly added to the therapeutic armamentarium of anti-cancer therapies. Targeting BCR-ABL in chronic myeloid leukemia (CML) or HER2 in breast cancer has led to practice-changing clinical benefits, while promising therapeutic responses have been achieved by precision medicine approaches in EGFR mutant lung cancer, colorectal cancer and BRAF mutant melanoma. However, although initial therapeutic responses to targeted therapies can be substantial, many patients will develop disease progression within 6-12 months. An increasing application of powerful omics-based approaches and improving preclinical models have enabled the rapid identification of secondary resistance mechanisms. Herein, we discuss how this knowledge has translated into rational, novel treatment strategies for relapsed patients in genomically selected cancer populations.
Original languageEnglish
Pages (from-to)896-908
Number of pages13
JournalSeminars in Oncology
Volume42
Issue number6
Early online date25 Sep 2015
DOIs
Publication statusPublished - Dec 2015

Fingerprint

Neoplasms
Therapeutics
Precision Medicine
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Disease Progression
Colorectal Neoplasms
Melanoma
Lung Neoplasms
Breast Neoplasms
Population

Cite this

@article{d4e20b4e048441d79546e52abb0f24be,
title = "Overcoming Resistance to Targeted Therapies in Cancer",
abstract = "The recent discovery of oncogenic drivers and subsequent development of novel targeted strategies has significantly added to the therapeutic armamentarium of anti-cancer therapies. Targeting BCR-ABL in chronic myeloid leukemia (CML) or HER2 in breast cancer has led to practice-changing clinical benefits, while promising therapeutic responses have been achieved by precision medicine approaches in EGFR mutant lung cancer, colorectal cancer and BRAF mutant melanoma. However, although initial therapeutic responses to targeted therapies can be substantial, many patients will develop disease progression within 6-12 months. An increasing application of powerful omics-based approaches and improving preclinical models have enabled the rapid identification of secondary resistance mechanisms. Herein, we discuss how this knowledge has translated into rational, novel treatment strategies for relapsed patients in genomically selected cancer populations.",
author = "Redmond, {Keara L.} and Anastasia Papafili and Mark Lawler and {Van Schaeybroeck}, Sandra",
year = "2015",
month = "12",
doi = "10.1053/j.seminoncol.2015.09.028",
language = "English",
volume = "42",
pages = "896--908",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "6",

}

Overcoming Resistance to Targeted Therapies in Cancer. / Redmond, Keara L.; Papafili, Anastasia; Lawler, Mark; Van Schaeybroeck, Sandra.

In: Seminars in Oncology, Vol. 42, No. 6, 12.2015, p. 896-908.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Overcoming Resistance to Targeted Therapies in Cancer

AU - Redmond, Keara L.

AU - Papafili, Anastasia

AU - Lawler, Mark

AU - Van Schaeybroeck, Sandra

PY - 2015/12

Y1 - 2015/12

N2 - The recent discovery of oncogenic drivers and subsequent development of novel targeted strategies has significantly added to the therapeutic armamentarium of anti-cancer therapies. Targeting BCR-ABL in chronic myeloid leukemia (CML) or HER2 in breast cancer has led to practice-changing clinical benefits, while promising therapeutic responses have been achieved by precision medicine approaches in EGFR mutant lung cancer, colorectal cancer and BRAF mutant melanoma. However, although initial therapeutic responses to targeted therapies can be substantial, many patients will develop disease progression within 6-12 months. An increasing application of powerful omics-based approaches and improving preclinical models have enabled the rapid identification of secondary resistance mechanisms. Herein, we discuss how this knowledge has translated into rational, novel treatment strategies for relapsed patients in genomically selected cancer populations.

AB - The recent discovery of oncogenic drivers and subsequent development of novel targeted strategies has significantly added to the therapeutic armamentarium of anti-cancer therapies. Targeting BCR-ABL in chronic myeloid leukemia (CML) or HER2 in breast cancer has led to practice-changing clinical benefits, while promising therapeutic responses have been achieved by precision medicine approaches in EGFR mutant lung cancer, colorectal cancer and BRAF mutant melanoma. However, although initial therapeutic responses to targeted therapies can be substantial, many patients will develop disease progression within 6-12 months. An increasing application of powerful omics-based approaches and improving preclinical models have enabled the rapid identification of secondary resistance mechanisms. Herein, we discuss how this knowledge has translated into rational, novel treatment strategies for relapsed patients in genomically selected cancer populations.

U2 - 10.1053/j.seminoncol.2015.09.028

DO - 10.1053/j.seminoncol.2015.09.028

M3 - Article

C2 - 26615134

VL - 42

SP - 896

EP - 908

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 6

ER -